Palladium Partners LLC Acquires 11,645 Shares of Pfizer, Inc. (PFE)

Palladium Partners LLC increased its holdings in Pfizer, Inc. (NYSE:PFE) by 1.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 617,758 shares of the biopharmaceutical company’s stock after purchasing an additional 11,645 shares during the period. Pfizer makes up 1.6% of Palladium Partners LLC’s investment portfolio, making the stock its 16th biggest holding. Palladium Partners LLC’s holdings in Pfizer were worth $20,751,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of PFE. Boston Partners boosted its holdings in Pfizer by 7.3% in the first quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock worth $830,071,000 after purchasing an additional 1,649,801 shares in the last quarter. Sanders Capital LLC boosted its holdings in Pfizer by 10.8% in the second quarter. Sanders Capital LLC now owns 16,933,077 shares of the biopharmaceutical company’s stock worth $626,222,000 after purchasing an additional 1,644,036 shares in the last quarter. Bank of Nova Scotia boosted its holdings in Pfizer by 325.9% in the first quarter. Bank of Nova Scotia now owns 1,934,514 shares of the biopharmaceutical company’s stock worth $66,180,000 after purchasing an additional 1,480,258 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in Pfizer by 3.9% in the second quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock worth $1,143,248,000 after purchasing an additional 1,275,832 shares in the last quarter. Finally, Longview Partners Guernsey LTD boosted its holdings in Pfizer by 6.9% in the second quarter. Longview Partners Guernsey LTD now owns 18,468,572 shares of the biopharmaceutical company’s stock worth $620,359,000 after purchasing an additional 1,189,059 shares in the last quarter. Hedge funds and other institutional investors own 69.01% of the company’s stock.

A number of brokerages recently issued reports on PFE. Deutsche Bank AG set a $38.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. BMO Capital Markets set a $37.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, October 10th. Barclays PLC set a $38.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, Jefferies Group LLC set a $38.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a report on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $38.35.

In related news, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the sale, the insider now directly owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The disclosure for this sale can be found here. Insiders have sold a total of 464,521 shares of company stock valued at $15,813,961 in the last ninety days. 0.06% of the stock is currently owned by insiders.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. Pfizer’s revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.61 EPS.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 3.65%. The ex-dividend date is Thursday, November 9th. Pfizer’s payout ratio is 94.12%.

TRADEMARK VIOLATION WARNING: “Palladium Partners LLC Acquires 11,645 Shares of Pfizer, Inc. (PFE)” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://sportsperspectives.com/2017/11/02/palladium-partners-llc-acquires-11645-shares-of-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply